Current Cardiology Reports

, 21:125 | Cite as

Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?

  • Sergey Kachur
  • Daniel P. MorinEmail author
Invasive Electrophysiology and Pacing (EK Heist, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Invasive Electrophysiology and Pacing


Purpose of Review

To discuss the role of wearable cardioverter defibrillator (WCD) vests in preventing sudden cardiac death (SCD) in at-risk populations.

Recent Findings

The impact of randomized-controlled trials with implantable cardioverter-defibrillators (ICD) therapy is well established in randomized clinical trials in ischemic cardiomyopathy. Although the benefits are not as clear in non-ischemic cardiomyopathy, meta-analyses show significant mortality benefits from immediate electrical cardioversion strategies. The role of WCDs in at-risk populations in whom ICD therapy is temporarily not indicated is not as well-established. Smaller cohort trials have shown efficacy in patients with newly-diagnosed cardiomyopathy, requiring temporary ICD explantation, and others with less common indications for WCD therapy.


The Vest Prevention of Early Sudden Death Trial was a landmark randomized control study seeking to examine the benefits of WCD therapy in at-risk population, and although the primary endpoint of reducing arrhythmic death was not reached, the structure of the trial and significant differences in total mortality make a compelling case for continued use of WCD therapies in our healthcare systems.


Wearable cardioverter-defibrillator Sudden cardiac death Ventricular arrhythmias Ischemic heart disease Implantable cardioverter-defibrillator 


Compliance with Ethical Standards

Conflict of Interest

Sergey Kachur has no disclosures.

Daniel P. Morin reports research grants from Medtronic and Boston Scientific, is a consultant for Abbott, and has received speaker honoraria from Medtronic and ZOLL. Also, Dr. Morin served on the steering committee for the VEST trial, and was one of the authors of the main VEST study manuscript (October 2018, N Engl J Med).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Adabag AS, Luepker RV, Roger VL, Gersh BJ. Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol. 2010 Apr;7(4):216–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cardiac Arrest: An important public health issue [internet]. Centers for Disease Control; Available from:
  3. 3.
    Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303(6):322–4.CrossRefPubMedGoogle Scholar
  4. 4.
    •• Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e190–252 A collection of the most-updated American guidelines on management of patients at-risk for sudden cardiac death. These recommendations precede the results of the VEST trials. CrossRefPubMedGoogle Scholar
  5. 5.
    • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12):781–8 Was one of the first trial to establish the lack of efficacy of anti-arrhythmics at preventing arrhythmic death. This trial helped stimulate the search for better alternatives.CrossRefPubMedGoogle Scholar
  6. 6.
    Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349(9053):675–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Julian D, Camm A, Frangin G, Janse M, Munoz A, Schwartz P, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349(9053):667–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335(26):1933–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341(25):1882–90.CrossRefPubMedGoogle Scholar
  10. 10.
    • Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83 One of the key randomized controlled trials that showed a benefit in patients with ischemic cardiomyopathy without testing for inducible arrhythmias. This is one of the cornerstones of the Class Ia ICD recommendation in this patient group. CrossRefPubMedGoogle Scholar
  11. 11.
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E, Rangel-Sousa D, Esteve-Ruiz IM, et al. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation. Transplant Proc. 2013;45(10):3659–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144(3):440–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002;112(7):519–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. [Internet]. Southampton, UK: Queen’s Printer and Controller of HMSO; 2006. (NIHR Health Technology Assessment programme: Executive Summaries.; vol. 10). Available from:
  16. 16.
    O’Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103(10):1416–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Wyse DG, Friedman PL, Brodsky MA, Beckman KJ, Carlson MD, Curtis AB, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38(6):1718–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361(15):1427–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Brooks GC, Lee BK, Rao R, Lin F, Morin DP, Zweibel SL, et al. Predicting persistent left ventricular dysfunction following myocardial infarction: the PREDICTS study. J Am Coll Cardiol. 2016;67(10):1186–96.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lewis GF, Harless AC, Vazquez L, Abi-Samra FM, Bernard ML, Khatib S, et al. Natural history and implantable cardioverter-defibrillator implantation after revascularization for stable coronary artery disease with depressed ejection fraction. Clin Cardiol. 2015;38(12):715–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation. 2002;105(12):1453–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874–9.CrossRefPubMedGoogle Scholar
  28. 28.
    •• Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135(2):201–3 A key recent meta-analysis that helps codify the benefits of implantable cardioverter-defibrillator therapy in the non-ischemic population. CrossRefPubMedGoogle Scholar
  29. 29.
    Myerburg RJ, Reddy V, Castellanos A. Indications for implantable cardioverter-defibrillators based on evidence and judgment. J Am Coll Cardiol. 2009;54(9):747–63.CrossRefPubMedGoogle Scholar
  30. 30.
    Srinivasan NT, Schilling RJ. Sudden cardiac death and arrhythmias. Arrhythmia Electrophysiol Rev. 2018;7(2):111–7.CrossRefGoogle Scholar
  31. 31.
    Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016;133(17):1715–27.CrossRefPubMedGoogle Scholar
  32. 32.
    Feldman AM, Klein H, Tchou P, Murali S, Hall WJ, Mancini D, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27(1):4–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Epstein AE, Abraham WT, Bianco NR, Kern KB, Mirro M, Rao SV, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol. 2013;62(21):2000–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, et al. Aggregate national experience with the wearable cardioverter-defibrillator. J Am Coll Cardiol. 2010;56(3):194–203.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Klein HU, Meltendorf U, Reek S, Smid J, Kuss S, Cygankiewicz I, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. 2010;33(3):353–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012;18(1):21–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Mitrani RD, Mcardle A, Slane M, Cogan J, Myerburg RJ. Wearable defibrillators in uninsured patients with newly diagnosed cardiomyopathy or recent revascularization in a community medical center. Am Heart J. 2013;165(3):386–92.CrossRefPubMedGoogle Scholar
  38. 38.
    Rao M, Goldenberg I, Moss AJ, Klein H, Huang DT, Bianco NR, et al. Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol. 2011;108(11):1632–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, et al. VALsartan in acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003;5(4):537–44.CrossRefPubMedGoogle Scholar
  40. 40.
    •• Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–15 The VEST trial is the only randomized-controlled clinical trial testing the efficacy of wearable cardioverter-defibrillator devices in at risk patients not eligible for ICD therapy with mortality endpoints. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57(13):1468–76.CrossRefPubMedGoogle Scholar
  42. 42.
    Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331(23):1564–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cardiovascular Diseases, John Ochsner Heart and Vascular InstituteOchsner Medical CenterNew OrleansUSA
  2. 2.Ochsner Clinical SchoolThe University of Queensland School of MedicineNew OrleansUSA
  3. 3.Division of Electrophysiology, Department of CardiologyNew OrleansUSA

Personalised recommendations